Comparative Pharmacology
Head-to-head clinical analysis: POSFREA versus VORICONAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POSFREA versus VORICONAZOLE.
POSFREA vs VORICONAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
POSFREA is a carbapenem-class antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
Inhibits fungal CYP450-dependent 14α-lanosterol demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
IV 4 mg/kg once daily; infused over 90 minutes.
Loading dose: 6 mg/kg IV every 12 hours for 2 doses, then maintenance 4 mg/kg IV every 12 hours; or 200–300 mg PO every 12 hours (400 mg PO every 12 hours for first 24 hours as loading dose if no IV).
None Documented
None Documented
12 hours (range 10-14) in healthy adults; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Clinical Note
moderateVoriconazole + Tranilast
"The risk or severity of adverse effects can be increased when Voriconazole is combined with Tranilast."
Clinical Note
moderateVoriconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Voriconazole is combined with Tolfenamic acid."
Clinical Note
moderateVoriconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Voriconazole is combined with Nimesulide."
Clinical Note
moderateThe terminal elimination half-life is approximately 6 hours for CYP2C19 extensive metabolizers. In poor metabolizers (which occur in 15-20% of Asian populations), the half-life can be prolonged to up to 24 hours. Clinical context: Dosing adjustments may be necessary based on CYP2C19 genotype; the short half-life necessitates twice-daily dosing for most patients.
Renal (95%) as unchanged drug; biliary/fecal (5%).
Voriconazole is primarily metabolized in the liver via CYP2C19, CYP3A4, and to a lesser extent CYP2C9. Less than 2% of the dose is excreted unchanged in urine. Fecal excretion accounts for approximately 20% of the dose, with the remainder as metabolites in urine. Overall, renal elimination of unchanged drug is negligible, but metabolites are excreted renally.
Category C
Category D/X
Azole Antifungal
Azole Antifungal
Voriconazole + Risedronic acid
"The risk or severity of adverse effects can be increased when Voriconazole is combined with Risedronic acid."